359 related articles for article (PubMed ID: 15995325)
41. Hypereosinophilic syndrome and proliferative diseases.
Ionescu MA; Wang L; Janin A
Acta Dermatovenerol Croat; 2009; 17(4):323-30. PubMed ID: 20021987
[TBL] [Abstract][Full Text] [Related]
42. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2022 Jan; 97(1):129-148. PubMed ID: 34533850
[TBL] [Abstract][Full Text] [Related]
43. Eosinophilic myeloid disorders.
Noel P
Semin Hematol; 2012 Apr; 49(2):120-7. PubMed ID: 22449622
[TBL] [Abstract][Full Text] [Related]
44. Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review.
Savage N; George TI; Gotlib J
Int J Lab Hematol; 2013 Oct; 35(5):491-500. PubMed ID: 23489324
[TBL] [Abstract][Full Text] [Related]
45. Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions.
Score J; Walz C; Jovanovic JV; Jones AV; Waghorn K; Hidalgo-Curtis C; Lin F; Grimwade D; Grand F; Reiter A; Cross NC
Leukemia; 2009 Feb; 23(2):332-9. PubMed ID: 18987650
[TBL] [Abstract][Full Text] [Related]
46. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2017 Nov; 92(11):1243-1259. PubMed ID: 29044676
[TBL] [Abstract][Full Text] [Related]
47. [Hematological disorders and hypereosinophilias].
Malfuson JV; Fagot T; Konopacki J; Mangouka L; Souleau B; de Revel T
Rev Med Interne; 2009 Apr; 30(4):322-30. PubMed ID: 19201511
[TBL] [Abstract][Full Text] [Related]
48. A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia.
Kalac M; Quintás-Cardama A; Vrhovac R; Kantarjian H; Verstovsek S
Cancer; 2007 Sep; 110(5):955-64. PubMed ID: 17654661
[TBL] [Abstract][Full Text] [Related]
49. Chronic myeloproliferative disorders: the role of tyrosine kinases in pathogenesis, diagnosis and therapy.
Macdonald D; Cross NC
Pathobiology; 2007; 74(2):81-8. PubMed ID: 17587879
[TBL] [Abstract][Full Text] [Related]
50. Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate.
Rathe M; Kristensen TK; Møller MB; Carlsen NL
Pediatr Blood Cancer; 2010 Oct; 55(4):730-2. PubMed ID: 20589620
[TBL] [Abstract][Full Text] [Related]
51. Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders.
Kelemen K; Saft L; Craig FE; Orazi A; Nakashima M; Wertheim GB; George TI; Horny HP; King RL; Quintanilla-Martinez L; Wang SA; Rimsza LM; Reichard KK
Am J Clin Pathol; 2021 Feb; 155(2):179-210. PubMed ID: 33367563
[TBL] [Abstract][Full Text] [Related]
52. Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion.
Lahortiga I; Akin C; Cools J; Wilson TM; Mentens N; Arthur DC; Maric I; Noel P; Kocabas C; Marynen P; Lessin LS; Wlodarska I; Robyn J; Metcalfe DD
Haematologica; 2008 Jan; 93(1):49-56. PubMed ID: 18166785
[TBL] [Abstract][Full Text] [Related]
53. Platelet-derived growth factor receptor-alpha-associated hypereosinophilic syndrome and lymphomatoid papulosis.
McPherson T; Cowen EW; McBurney E; Klion AD
Br J Dermatol; 2006 Oct; 155(4):824-6. PubMed ID: 16965435
[TBL] [Abstract][Full Text] [Related]
54. Hypereosinophilic syndrome: diagnosis and treatment.
Peros-Golubicić T; Smojver-Jezek S
Curr Opin Pulm Med; 2007 Sep; 13(5):422-7. PubMed ID: 17940488
[TBL] [Abstract][Full Text] [Related]
55. Management of Hypereosinophilic Syndromes.
Roufosse F
Immunol Allergy Clin North Am; 2015 Aug; 35(3):561-75. PubMed ID: 26209900
[TBL] [Abstract][Full Text] [Related]
56. Eosinophilic myeloid neoplasms.
Noel P; Mesa RA
Curr Opin Hematol; 2013 Mar; 20(2):157-62. PubMed ID: 23385615
[TBL] [Abstract][Full Text] [Related]
57. Management of F/P+/- hypereosinophilic syndromes: case report and treatment review.
Kalra A; Palaniswamy C; Kalra A; Wig N; Sood R
Am J Ther; 2012 Sep; 19(5):e146-51. PubMed ID: 20724910
[TBL] [Abstract][Full Text] [Related]
58. Hypereosinophilic syndrome, chronic eosinophilic leukemia, and mast cell disease.
Pardanani A; Verstovsek S
Cancer J; 2007; 13(6):384-91. PubMed ID: 18032976
[TBL] [Abstract][Full Text] [Related]
59. Diagnostic complexities of eosinophilia.
Montgomery ND; Dunphy CH; Mooberry M; Laramore A; Foster MC; Park SI; Fedoriw YD
Arch Pathol Lab Med; 2013 Feb; 137(2):259-69. PubMed ID: 23368869
[TBL] [Abstract][Full Text] [Related]
60. A case of myeloid neoplasm with FIP1L1-PDGFRA rearrangement without marked peripheral blood eosinophilia.
Wang J; Zhang Q; Zeng H; Chen B; Ouyang J
Pharmacogenomics; 2016; 17(2):99-102. PubMed ID: 26666578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
